FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

FDA decision on DTX401 (pariglasgene brecaparvovec) in 2026 If the FDA's decision on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. DTX401 (pariglasgene brecaparvovec) is a one-time gene therapy developed by Ultragenyx Pharmaceutic